Quantitative proteomic profiling of KZR-540, a novel small molecule oral Sec61 inhibitor that selectively inhibits PD-1 expression (SITC 2023) - Sep 27, 2023 - Abstract #522; Pres time: Nov 4, 2023; 09:00 AM - 08:30 PM; Location: Exhibit Hall B; P1 | "1 Here we utilized LC/MS-based quantitative proteomic profiling to study the unique selectivity of KZR-540 in contrast to the promiscuous Sec61 inhibitor KZR-261 and its analog KZR-834. KZR-261 is currently being evaluated in a phase-1 clinical trial in solid tumors (NCT05047536). Follow-up in vivo studies will examine the differential impact of KZR-540 and KZR-261/834 on the tumor-draining lymph nodes (TDLNs) and plasma proteomes of human-PD-1 knock-in mice bearing human-PD-L1 MC38 tumors."
IO biomarker • Oncology • Solid Tumor • PD-L1 • SEC61G
|
|
David L Bade; Neel K Anand; Cristina Delgado Martin; Christopher Kirk; Yu Qian; Vaishnavi Beena Valsan; Jinhai Wang; Patricia Zuno-Mitchell
|